Calcimimetics versus Vitamin D: What Are Their Relative Roles?
- 20 January 2004
- journal article
- research article
- Published by S. Karger AG in Blood Purification
- Vol. 22 (1), 38-43
- https://doi.org/10.1159/000074922
Abstract
A strict control of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) is indicated to avoid serious complications linked to osteitis fibrosa and other parathyroid-hormone (PTH)-related bodily disturbances. However, such a control is often achieved only at the price of unacceptably high plasma calcium and phosphorus levels and the risk of soft tissue calcification, even when using the novel, so-called ‘non-hypercalcemic’ vitamin D analogs. The advent of a new class of drugs, the calcimimetics, should allow a more adequate control of the disturbed calcium-phosphorus metabolism in CKD patients. In my opinion, the calcimimetics will not replace currently used medications but will be a valuable supplement to presently available treatment options for this major complication in patients with renal failure.Keywords
This publication has 9 references indexed in Scilit:
- Survival of Patients Undergoing Hemodialysis with Paricalcitol or Calcitriol TherapyNew England Journal of Medicine, 2003
- Modulation of Growth Factor/Cytokine Synthesis and Signaling by 1α,25-Dihydroxyvitamin D3: Implications in Cell Growth and DifferentiationEndocrine Reviews, 2002
- Differential effects of 19-nor-1,25-(OH)2D2 and 1alpha-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic ratsKidney International, 2002
- Adynamic Bone and Chronic Renal Failure: An OverviewThe American Journal of the Medical Sciences, 2000
- Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing DialysisNew England Journal of Medicine, 2000
- Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidismKidney International, 2000
- NPS R-568 halts or reverses osteitis fibrosa in uremic ratsKidney International, 1998
- A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure: Rapid CommunicationKidney International, 1998
- Intermittent intravenous followed by intermittent oral 1α(OH)D3 treatment of secondary hyperparathyroidism in uraemiaJournal of Internal Medicine, 1996